News

ISOThrive Awarded Composition of Matter and Production Method Patent for its First “Farmaceutical™” to Support Animal Health

ISOThrive Inc., a microbiome therapeutics company announced that the U.S. Patent and Trademark Office has issued a Composition of Matter and Production Method patent for its first Farmaceutical™ Maltosyl-Isomaltooligosaccharides (MIMO™), a prebiotic for use as an animal feed additive and pet food supplement. USDA and University of GA studies showed MIMO as highly effective at protecting chickens against antibiotic resistant Salmonella while improving feed efficiency.

ISOThrive opens up a whole new market opportunity to offer higher quality meats that are free of pathogens and also leaner. At the same time, increased food safety is better for workers, less costly for producers and better for the environment. Plus, there are emerging opportunities in pet health with supplements that support better digestion with less reliance on medications.

The widespread use of antibiotics in cattle, swine and chickens can lead to the creation of antibiotic resistant bacterial species.  The same antibiotics used in animal feed are also used to treat disease in humans. With the rise of antibiotic resistant bacteria, eliminating their use in livestock has become a necessity. Prebiotics, while offering a viable alternative to antibiotics, can be expensive to manufacture. This patent covers an economical and efficient method for making (MIMO) that can be used as an additive for animal feed at significantly lower cost.

“Today’s conscious consumer wants a healthier food supply, a better environment for the people that produce the food and has the least amount of environmental impact,” said Jack Oswald, ISOThrive’s CEO, CTO and Co-Founder. “This new patent allows us to open a new market opportunity while simultaneously positively impacting food safety and security at a cost that makes sense for producers.”

Researchers at USDA and University of Georgia found that MIMO added to chicken feed reduced antibiotic resistant Salmonella by 99% while increasing Bifidobacteria.  Feed efficiency was increased by 9-10%.

 

Recent News

03/23/2023

Children’s National Hospital names Michelle Riley-Brown as new CEO to succeed Kurt Newman

The Children’s National Board of Directors announced that Michelle Riley-Brown, MHA, FACHE, has been named as the new president and chief executive officer (CEO) of Children’s National Hospital. On July 1, Riley-Brown will succeed Kurt Newman, M.D. , who is retiring after 11 years as president and CEO. Riley-Brown is an accomplished executive with over

03/21/2023

Mason leads planning study to position Northern Virginia as a premier location for the life science industry

During the past several years, industry demand for a skilled life science workforce has been surging. In Virginia, while there are currently shortages in almost all health-related professions, little is known about whether there is an adequate supply of life science workers to meet the needs of employers. Now George Mason University is working toward

03/21/2023

California invests $50M to partner with Civica Rx on insulin manufacturing

California Gov. Gavin Newsom has announced a new contract with nonprofit drugmaker Civica Rx, a move that brings the state one step closer to creating its own line of insulin to bring down the cost of the drug. Once the medicines are approved by the Food and Drug Administration, Newsom said at a press conference